In three previous blog posts, we have discussed recent inventorship issues surrounding Artificial Intelligence (“AI”) and its implications for life sciences innovations – focusing specifically on scientist Stephen Thaler’s attempt to obtain a patent for an invention created by his AI system called DABUS (“Device for Autonomus Bootstrapping of Unified Sentence). Most recently, we considered Thaler’s appeal of the September 3, 2021 decision out of the Eastern District of Virginia, which ruled that under the Patent Act, an AI machine cannot qualify as an “inventor.” Continuing this series, we now consider the USPTO’s recently filed opposition to Thaler’s appeal.

In its opposition brief, the USPTO argued that under the “plain language Congress chose to incorporate in the Patent Act,” only a human being can be considered an “inventor.” The USPTO first noted that the definitions of “inventor” and “joint inventor” under the Patent Act both unequivocally refer only to an “individual” or “individuals.” For example, “inventor” is defined under the Act as “the individual or, if a joint invention, the individuals collectively who invented or discovered the subject matter of the invention.”

While the Patent Act does not explicitly define the term “individual,” the USPTO argued that in other instances where the term is not explicitly defined, courts have interpreted Congress’s use of the term “individual” in a given statute as denoting a “human being,” as opposed to other things. The USPTO provided the example of Mohamad v. Palestinian Auth., a 2012 case in which the Supreme Court evaluated whether Congress’s use of the term “individual in the Torture Victim Protection Act (“TVPA”) could be construed to include an “organization.” There, the Court quoted from several well-known dictionaries and considered the use of the term in “everyday parlance,” to determine that the ordinary meaning of the term “individual” refers only to a human being or natural person. The Court in Mohamad also referred to the Dictionary Act, 1 U.S.C. § 1, which provides that the legislative use of the term “individual” denotes something separate and apart from non-human beings.

The USPTO argued that the Supreme Court’s analysis in Mohamad is equally applicable to the Patent Act as it is to the TVPA. For example, the term “individual” is used in the Patent Act as a noun, just as it is in the TVPA. And, according to the USPTO, just as the Mohamad Court recognized “no one…refers in normal parlance to an organization as an ‘individual,’” it is equally true that “no one… refers in normal parlance” to a machine or collection of source code as an “individual.” Further, the USPTO pointed out that the Dictionary Act applies not only to the TVPA, but to all congressional enactments – including the Patent Act.

Though the Supreme Court’s opinion in Mohamad acknowledges that Congress is free to give the term “individual” a “broader or different meaning,” such “broader” construction by a court requires some affirmative “indication [that Congress] intended such a result.” Here, the USPTO argues that Thaler has never pointed to any textual evidence that Congress intended a broader meaning for the term. The USPTO argues that Thaler has only put forth non-textual policy arguments. For example, Thaler argues that denying inventorship to AI would place the United States behind “other countries [that] are promoting the progress of science,” and would amount to “adopt[ing] luddism.” However, according to the USPTO, these policy considerations cannot overcome the plain meaning of the text.

We will continue to monitor this appeal, as it has important implications for life sciences companies employing AI technologies, particularly given the low probability that Congress will act on this issue in the short term.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Baldassare Vinti Baldassare Vinti

Baldassare (“Baldo”) Vinti is the head of Proskauer’s Intellectual Property Litigation Group.

Baldo is a first-chair trial lawyer known for navigating complex, bet-the-company intellectual property disputes across industry verticals and next-generation technologies. With over 25 years of experience, Baldo represents leading global companies…

Baldassare (“Baldo”) Vinti is the head of Proskauer’s Intellectual Property Litigation Group.

Baldo is a first-chair trial lawyer known for navigating complex, bet-the-company intellectual property disputes across industry verticals and next-generation technologies. With over 25 years of experience, Baldo represents leading global companies and universities in patent, trade secret, false advertising, consumer class actions and technology-related breach of contract litigation in federal and state courts as well as before the International Trade Commission.

Baldo is particularly sought after for his courtroom skill and strategic depth, having led trials, arbitrations and appeals in high-stakes disputes involving technologies ranging from pharmaceuticals and medical devices to encryption, digital media, diagnostics, mobile platforms and software. Baldo has represented global corporations, including Arkema S.A., British Telecommunications PLC, Church & Dwight Co., Inc., Henry Schein, Inc., Maidenform Brands Inc., Mitsubishi Electric Corp., Ossur North America Inc., Panasonic Corp., Sony Corp., Welch Foods, Inc. and Zenith Electronics LLC.

With a background in pharmacy, Baldo brings deep domain expertise to pharmaceutical litigation. He has a proven record of driving successful outcomes in complex pharmaceutical milestone payment, royalty and licensing disputes—often stemming from collaboration agreements, co-development deals, and M&A transactions—where the financial and strategic stakes run high.

In addition to representing corporate clients, Baldo works closely with university innovation and technology transfer offices to maximize the financial return of research investments. He develops tailored IP asset optimization strategies and aggressively enforces intellectual property rights to protect and monetize core innovations—whether through high-value licensing agreements, shaping and advancing spin-out company development, or successful litigation.

Baldo also provides strategic counsel on IP due diligence, complex licensing, IP structuring, patentability and freedom-to-operate analyses, and infringement and validity opinions. He advises boards and executive teams on aligning IP strategy with business objectives, mitigating risk and maximizing the value of innovation assets.

A frequent author and commentator on intellectual property topics, Baldo has been quoted in the National Law Journal, Bloomberg BNA, Law360, Westlaw Journal and Inside Counsel magazine. He is also a regular contributor to articles published in Medical Product Outsourcing magazine that deal with the medical device industry.

Baldo served as a judicial intern for Hon. John E. Sprizzo of the United States District Court for the Southern District of New York and for Hon. Charles A. LaTorella of the New York Supreme Court.